Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 163, Issue 5, Pages 631-639Publisher
WILEY
DOI: 10.1111/bjh.12591
Keywords
chronic myeloid leukaemia; tyrosine kinases; prognostic factors; drug resistance
Categories
Funding
- NIHR Biomedical Research Centre Funding Scheme
- Cancer Research UK [10411] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0611-10275] Funding Source: researchfish
Ask authors/readers for more resources
Approximately one-third of patients with chronic myeloid leukaemia will fail to achieve or maintain responses to imatinib. Changes in solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also termed OCT1), the main transporter for imatinib, have been proposed as a possible predictive factor. We analysed SLC22A1 mRNA levels and single nucleotide polymorphisms (SNPs) located in exon 7 in 153 diagnostic whole blood samples from two patient cohorts. The level of SLC22A1 expression did not significantly correlate with imatinib failure or achievement of molecular remission. The SNP 408V>M (g.1222G>A) was present in 65% of patients and was associated in all cases with an eight base-pair insertion (8(+) allele) at the 3 end of exon 7. The latter generates an alternative splice site, leading to a premature stop codon. M420del was found in 33% of patients and never in cis with 8(+) (the 3(-) allele). Significantly longer times to 1% and 01% molecular responses (by quantitative reverse transcription polymerase chain reaction) were seen in patients with 8(+)8(+) or 8(+)N compared to those with the remaining four genotypes (N=no insertion or deletion). Patients lacking 8(+) and 3(-) (NN, 18%) showed the best outcomes overall. Thus, while SLC22A1 expression does not appear to affect response, alterations in its splicing or amino acid sequence may do so.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available